MRMatheus Roque

Matheus Roque

*This is an algorithmically generated author record based on publicly available information.

Matheus Roque has a total of 204 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Intramuscular progesterone and frozen embryo transfer outcomes: A multicenter prospective evaluation of the clinical relevance of serum progesterone monitoring

    by Vipin Chandra, Matheus Roque, Kshitiz Murdia, Nitiz Murdia, Shashank V. Sanagoudar, Nagadeepti Naik, Shipra Nigam, Anjali Gahlan, Walmik Mistari, Isha Suwalka, et al.

    The progesterone concentration in endometrial tissue after using vaginal progesterone supplementation is significantly higher than that with IM progesterone administration, whereas; serum progesterone levels are approximately four times higher with IM progesterone compared with vaginal administration. Therefore, serum progesterone cut-off points will differ according to the route of progesterone administration. This study aims to assess the association between serum progesterone levels on the day of frozen embryo transfer (FET) and pregnancy outcomes in artificial FET cycles. This multicenter prospective cohort study, conducted at different centers of Indira IVF Hospitals across India, included 353 women aged 21–40 years who underwent hormone replacement therapy-based FET cycles with intramuscular (IM) progesterone administered up to the day of embryo transfer. The mean serum progesterone level was 31.36 ± 13.78 ng/mL. Participants were categorized into quartiles based on serum progesterone levels: Q1 (<21.7 ng/mL), Q2 (21.7–28.1 ng/mL), Q3 (28.2–40.0 ng/mL), and Q4 (≥40.0 ng/mL). No significant differences in ongoing pregnancy rate (OPR), clinical pregnancy rate (CPR), first-trimester miscarriage rates, or live birth rate (LBR) were observed across the quartiles. Binary logistic regression revealed no statistically significant differences in OPR among the quartiles. Our findings suggest that serum progesterone levels do not significantly influence clinical outcomes, including OPR, CPR, and LBR, in patients undergoing artificial FET cycles with IM progesterone support.

  • Open Access

    The most appropriate indicators of successful ovarian stimulation

    by Matheus Roque, Sesh K. Sunkara

    Ovarian stimulation (OS) is a crucial component of clinical IVF treatment that strongly influences outcomes. As such, it is useful to understand the indicators for successful OS during IVF. As OS leads to multiple follicular recruitment, it can be quantified as number of oocytes retrieved. Optimal OS should help to maximize the number of oocytes, thus improving preclinical laboratory outcomes. Optimal preclinical outcomes should ultimately lead to clinical outcomes with maximal efficacy, safety, and cost-effectiveness. To help guide successful OS, this review details prognostic factors and appropriate endpoints for an optimal OS at each stage of the IVF cycle.


  • Open Access

    Fresh versus elective frozen embryo transfer: Cumulative live birth rates of 7,236 IVF cycles

    by Thi Minh Chau Le, Phuc Thinh Ong, Quoc Anh Nguyen, Matheus Roque

    Objective: To determine whether elective frozen embryo transfer (eFET), or the 'freeze-all' strategy, associated with better cumulative clinical outcomes compared with fresh embryo transfer (ET). Methods: A total of 7,236 IVF cycles that were followed by a fresh ET or eFET between 2013 and 2017. The patients were subjected to controlled ovarian stimulation (COS) with a gonadotropin-releasing hormone (GnRH) antagonist protocol and cleavage-stage ET. Embryo cryopreservation was performed on day 3 by vitrification using an open system. A comparison of cumulative outcomes between the eFET (n=4,065cycles) and the fresh ET groups (n=3,171cycles) were performed. The analysis was performed in four groups of patients based on the number of retrieved oocytes: Group 1: poor responders (1-3 oocytes); Group 2: suboptimal responders (4-9 oocytes); Group 3: normal responders (10-15 oocytes); and Group 4: hyper-responders ( 15 oocytes). The primary outcome was the cumulative live birth rate (CLBR) per stimulated cycle. Results: There were a total of 10,283 ETs (n=5,639 eFET group; n=4,644 fresh group). The freeze-all strategy is associated with improved CLBRs in normal and hyper -responders, but not in suboptimal and poor responders. In Group 1, there were 351 IVF cycles and 387 ETs in total, and the CLBR was 14.3% and 17.7% (p=0.584) for the eFET and fresh group, respectively. In Group 2, there were 2,074 IVF cycles and 2,465 ET in total, and the CLBR was 25.1% and 23.3% (p=0.083) in the eFET and fresh group, respectively. There was a significant difference in the CLBR in Groups 3 and 4, favouring the eFET strategy. In Group 3, 2226 IVF cycles and 3243 ET were performed. The CLBR was 40.5% in the eFET and 36.6% in the fresh group (p<0.001). In Group 4, there were 2547 IVF cycles and 3,188 ET in total, and the CLBR was 52.2% and 47.7% (p<0.001) in the eFET and fresh group, respectively. The number needed to treat to achieve one additional live birth was 25.9 in Group 3 and 22.3 in Group 4. Conclusions: The implementation of the freeze-all strategy should be individualized. The freeze-all strategy is associated with improved CLBRs in normal and hyper -responders, but not in suboptimal and poor responders.


  • Open Access

    The POSEIDON stratification - moving from poor ovarian response to low prognosis

    by Matheus Roque, Thor Haahr, Sandro C. Esteves, Peter Humaidan

    Poor ovarian response remains one of the most challenging tasks for an IVF clinician. In this review, we aim to highlight the ongoing research for optimizing the prognosis in poor ovarian response patients. The newly introduced POSEIDON criteria argue that the first step is to move from a poor response to a poor prognosis concept, while improving identification and stratification of the different sub-types of poor prognosis patients prior to ovarian stimulation. The immediate marker of success is the ability of the ovarian stimulation to retrieve the number of oocytes needed to obtain at least one euploid blastocyst for transfer in each patient. This surrogate marker of success should not replace live birth as the most important outcome, but it should be approached as a useful tool for clinicians to evaluate their strategy for achieving live birth in the shortest timespan possible in the individual patient/couple.


  • Open Access

    COVID-19 and assisted reproductive technology services: repercussions for patients and proposal for individualized clinical management

    by on behalf of the POSEIDON (Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number) group, Carlo Alviggi, Sandro C. Esteves, Raoul Orvieto, Alessandro Conforti, Antonio La Marca, Robert Fischer, Claus Y. Andersen, Klaus Bühler, Sesh K. Sunkara, et al.

    The prolonged lockdown of health services providing high-complexity fertility treatments –as currently recommended by many reproductive medicine entities– is detrimental for society as a whole, and infertility patients in particular. Globally, approximately 0.3% of all infants born every year are conceived using assisted reproductive technology (ART) treatments. By contrast, the total number of COVID-19 deaths reported so far represents approximately 1.0% of the total deaths expected to occur worldwide over the first three months of the current year. It seems, therefore, that the number of infants expected to be conceived and born –but who will not be so due to the lockdown of infertility services– might be as significant as the total number of deaths attributed to the COVID-19 pandemic. We herein propose remedies that include a prognostic-stratification of more vulnerable infertility cases in order to plan a progressive restart of worldwide fertility treatments. At a time when preventing complications and limiting burdens for national health systems represent relevant issues, our viewpoint might help competent authorities and health care providers to identify patients who should be prioritized for the continuation of fertility care in a safe environment.


  • ICSI and Male Infertility: Consequences to Offspring

    by Giuliano Bedoschi, Matheus Roque, Sandro C. Esteves


  • Open Access

    Extended indications for sperm retrieval: summary of current literature

    by Sandro C. Esteves, Matheus Roque

    Sperm retrieval combined with intracytoplasmic sperm injection (ICSI) is the treatment of choice for couples with untreatable azoospermia-related infertility. However, an increasing body of evidence has been mounting, suggesting that ICSI with testicular sperm instead of ejaculated sperm (when both are available) increases pregnancy outcomes in some specific scenarios. This has led to the exploration of extended indications for sperm retrieval. This review summarizes the current literature concerning sperm retrieval and ICSI for non-azoospermic men with elevated sperm DNA fragmentation, oligozoospermia, and cryptozoospermia.


  • Open Access

    Oocyte quantity, as well as oocyte quality, plays a significant role for the cumulative live birth rate of a POSEIDON criteria patient

    by Sandro C Esteves, Matheus Roque, Sesh K Sunkara, Alessandro Conforti, Filippo M Ubaldi, Peter Humaidan, Carlo Alviggi


  • Top Cited Papers
    Open Access

    Male Oxidative Stress Infertility (MOSI): Proposed Terminology and Clinical Practice Guidelines for Management of Idiopathic Male Infertility

    by Ashok Agarwal, Neel Parekh, Manesh Kumar Panner Selvam, Ralf Henkel, Rupin Shah, Sheryl T. Homa, Ranjith Ramasamy, Edmund Ko, Kelton Tremellen, Sandro Esteves, et al.

    Agarwal A, et al. World J Mens Health. 2019 Sep;37(3):296-312. https://doi.org/10.5534/wjmh.190055


  • Freeze-all strategy in IVF/ICSI cycles: an update on clinical utility

    by Matheus Roque, Beatrice Nuto Nóbrega, Marcello Valle, Marcos Sampaio, Selmo Geber, Thor Haahr, Peter Humaidan, Sandro C. Esteves

    Over the years concerns have arisen about possible adverse effects associated with controlled ovarian stimulation (COS) as regards not only the endometrium, but also on obstetrical and perinatal outcomes in pregnancies after fresh embryo transfer (ET) during in-vitro fertilization (IVF) treatment. The improvements in cryopreservation techniques associated with the possible impairment in endometrial receptivity due to the supra-physiologic hormonal levels observed during conventional COS have increased the implementation of the so-called "freeze-all" policy. With this strategy, the entire cohort of embryos is cryopreserved to be transferred to the uterus in subsequent cycles in a more physiological environment, avoiding the supra-physiologic hormonal levels observed during COS. The initial studies showed that this strategy could be beneficial for subgroups of patients, however, the freeze-all policy is being more and more frequently used for all patient categories. Unfortunately, currently, no clinical data support this widespread use of the freeze-all strategy. Based on available trials, it seems justified to implement the strategy in patients with risk of ovarian hyperstimulation syndrome, hyper-responders and when performing preimplantation genetic testing for aneuploidy in blastocyst stage. Therefore, all the other indications, such as implantation failure, high progesterone levels on the trigger day, advanced maternal age, and endometriosis, still lack the evidence to support routine use of the freeze-all policy.